AAAAAA

   
Results: 1-25 | 26-29
Results: 1-25/29
REDUCED DOSE OF SUBCUTANEOUS CLADRIBINE INDUCES IDENTICAL RESPONSE RATES BUT DECREASED TOXICITY IN PRETREATED CHRONIC LYMPHOCYTIC-LEUKEMIA
Authors: BETTICHER DC RATSCHILLER D SCHMITZ SFH VONROHR A HESS U ZULIAN G WERNLI M TICHELLI A TOBLER A FEY MF CERNY T
Citation: Dc. Betticher et al., REDUCED DOSE OF SUBCUTANEOUS CLADRIBINE INDUCES IDENTICAL RESPONSE RATES BUT DECREASED TOXICITY IN PRETREATED CHRONIC LYMPHOCYTIC-LEUKEMIA, Annals of oncology, 9(7), 1998, pp. 721-726
FEWER INFECTIONS, BUT MAINTAINED ANTITUMOR-ACTIVITY WITH LOWER-DOSE VERSUS STANDARD-DOSE CLADRIBINE IN PRETREATED LOW-GRADE NON-HODGKINS-LYMPHOMA
Authors: BETTICHER DC VONROHR A RATSCHILLER D SCHMITZ SFH EGGER T SONDEREGGER T HERRMANN R KRONER T ZULIAN GB CAVALLI F FEY MF CERNY T
Citation: Dc. Betticher et al., FEWER INFECTIONS, BUT MAINTAINED ANTITUMOR-ACTIVITY WITH LOWER-DOSE VERSUS STANDARD-DOSE CLADRIBINE IN PRETREATED LOW-GRADE NON-HODGKINS-LYMPHOMA, Journal of clinical oncology, 16(3), 1998, pp. 850-858
2-CDA IN THE TREATMENT OF HAIRY-CELL LEUKEMIA - INTRAVENOUS VS SUBCUTANEOUS ADMINISTRATION
Authors: SPERB RA VONROHR A RATSCHILLER D BACCHI M TICHELLI A HESS U CERNY T TOBLER A BETTICHER DC
Citation: Ra. Sperb et al., 2-CDA IN THE TREATMENT OF HAIRY-CELL LEUKEMIA - INTRAVENOUS VS SUBCUTANEOUS ADMINISTRATION, Schweizerische medizinische Wochenschrift, 128(42), 1998, pp. 1593-1597
MYELODYSPLASTIC SYNDROME WITH BICLONAL MONOSOMY-7 AND TRISOMY-8 AFTERTREATMENT WITH CLADRIBINE (2-CHLORO-2-DEOXYADENOSINE) AND INVOLVED FIELD RADIATION-THERAPY
Authors: LAURENCET FM ZULIAN GB CABROL C BETTICHER DC
Citation: Fm. Laurencet et al., MYELODYSPLASTIC SYNDROME WITH BICLONAL MONOSOMY-7 AND TRISOMY-8 AFTERTREATMENT WITH CLADRIBINE (2-CHLORO-2-DEOXYADENOSINE) AND INVOLVED FIELD RADIATION-THERAPY, Cancer genetics and cytogenetics, 99(1), 1997, pp. 85-89
G(1) CONTROL GENE STATUS IS FREQUENTLY ALTERED IN RESECTABLE NONSMALLCELL LUNG-CANCER
Authors: BETTICHER DC WHITE GRM VONLANTHEN S LIU X KAPPELER A ALTERMATT HJ THATCHER N HEIGHWAY J
Citation: Dc. Betticher et al., G(1) CONTROL GENE STATUS IS FREQUENTLY ALTERED IN RESECTABLE NONSMALLCELL LUNG-CANCER, International journal of cancer, 74(5), 1997, pp. 556-562
CLADRIBINE (2-CDA) GIVEN AS SUBCUTANEOUS BOLUS INJECTIONS IS ACTIVE IN PRETREATED WALDENSTROMS MACROGLOBULINEMIA
Authors: BETTICHER DC SCHMITZ SFH RATSCHILLER D VONROHR A EGGER T PUGIN P STALDER M HESS U FEY MF CERNY T
Citation: Dc. Betticher et al., CLADRIBINE (2-CDA) GIVEN AS SUBCUTANEOUS BOLUS INJECTIONS IS ACTIVE IN PRETREATED WALDENSTROMS MACROGLOBULINEMIA, British Journal of Haematology, 99(2), 1997, pp. 358-363
ABNORMAL EXPRESSION OF CCND1 AND RB1 IN RESECTION MARGIN EPITHELIA OFLUNG-CANCER PATIENTS
Authors: BETTICHER DC HEIGHWAY J THATCHER N HASLETON PS
Citation: Dc. Betticher et al., ABNORMAL EXPRESSION OF CCND1 AND RB1 IN RESECTION MARGIN EPITHELIA OFLUNG-CANCER PATIENTS, British Journal of Cancer, 75(12), 1997, pp. 1761-1768
ECHINOCYTIC TRANSFORMATION AND AGGREGATION OF RED-CELLS IN UREMIC PATIENTS - REPLY
Authors: BETTICHER DC GEISER J REINHART WH
Citation: Dc. Betticher et al., ECHINOCYTIC TRANSFORMATION AND AGGREGATION OF RED-CELLS IN UREMIC PATIENTS - REPLY, Journal of applied physiology, 80(2), 1996, pp. 712-712
2-CHLORODEOXYADENOSINE (2-CDA) THERAPY IN PREVIOUSLY UNTREATED PATIENTS WITH FOLLICULAR STAGE III-IV NON-HODGKINS-LYMPHOMA
Authors: BETTICHER DC ZUCCA E VONROHR A EGGER T RADFORD JA AMBROSETTI A BURKI K RUFENER B SCHMITZ SFH CERNY T
Citation: Dc. Betticher et al., 2-CHLORODEOXYADENOSINE (2-CDA) THERAPY IN PREVIOUSLY UNTREATED PATIENTS WITH FOLLICULAR STAGE III-IV NON-HODGKINS-LYMPHOMA, Annals of oncology, 7(8), 1996, pp. 793-799
CYCLIN D1, ANOTHER MOLECULE OF THE YEAR
Authors: BETTICHER DC
Citation: Dc. Betticher, CYCLIN D1, ANOTHER MOLECULE OF THE YEAR, Annals of oncology, 7(3), 1996, pp. 223-225
COAMPLIFICATION IN TUMORS OF KRAS2, TYPE-2 INOSITOL 1,4,5-TRIPHOSPHATE RECEPTOR GENE, AND A NOVEL HUMAN GENE, KRAG
Authors: HEIGHWAY J BETTICHER DC HOBAN PR ALTERMATT HJ COWEN R
Citation: J. Heighway et al., COAMPLIFICATION IN TUMORS OF KRAS2, TYPE-2 INOSITOL 1,4,5-TRIPHOSPHATE RECEPTOR GENE, AND A NOVEL HUMAN GENE, KRAG, Genomics, 35(1), 1996, pp. 207-214
HIGH-LEVELS OF LOSS AT THE 17P TELOMERE SUGGEST THE CLOSE PROXIMITY OF A TUMOR-SUPPRESSOR
Authors: WHITE GRM STACK M SANTIBANEZKOREF M LISCIA DS VENESIO T WANG JC HELMS C DONISKELLER H BETTICHER DC ALTERMATT HJ HOBAN PR HEIGHWAY J
Citation: Grm. White et al., HIGH-LEVELS OF LOSS AT THE 17P TELOMERE SUGGEST THE CLOSE PROXIMITY OF A TUMOR-SUPPRESSOR, British Journal of Cancer, 74(6), 1996, pp. 863-870
PROGNOSTIC-SIGNIFICANCE OF CCND1 (CYCLIN D1) OVEREXPRESSION IN PRIMARY RESECTED NON-SMALL-CELL LUNG-CANCER
Authors: BETTICHER DC HEIGHWAY J HASLETON PS ALTERMATT HJ RYDER WDJ CERNY T THATCHER N
Citation: Dc. Betticher et al., PROGNOSTIC-SIGNIFICANCE OF CCND1 (CYCLIN D1) OVEREXPRESSION IN PRIMARY RESECTED NON-SMALL-CELL LUNG-CANCER, British Journal of Cancer, 73(3), 1996, pp. 294-300
EFFECT OF RBC SHAPE AND DEFORMABILITY ON PULMONARY O-2 DIFFUSING-CAPACITY AND RESISTANCE TO FLOW IN RABBIT LUNGS
Authors: BETTICHER DC REINHART WH GEISER J
Citation: Dc. Betticher et al., EFFECT OF RBC SHAPE AND DEFORMABILITY ON PULMONARY O-2 DIFFUSING-CAPACITY AND RESISTANCE TO FLOW IN RABBIT LUNGS, Journal of applied physiology, 78(3), 1995, pp. 778-783
DACARBAZINE AND INTERFERON-ALPHA 2A IN ADVANCED MALIGNANT-MELANOMA - HIGH RESPONSE RATE AND PROLONGATION OF RESPONSE DURATION OCCUR IN DIFFERENT PATIENT SUBPOPULATIONS
Authors: BETTICHER DC LEE SM MORRIS C CLEMONS M THATCHER N
Citation: Dc. Betticher et al., DACARBAZINE AND INTERFERON-ALPHA 2A IN ADVANCED MALIGNANT-MELANOMA - HIGH RESPONSE RATE AND PROLONGATION OF RESPONSE DURATION OCCUR IN DIFFERENT PATIENT SUBPOPULATIONS, Melanoma research, 5(4), 1995, pp. 277-282
A PHASE-II EVALUATION OF BONE-MARROW PROTECTION BY ETHYOL(R) (AMIFOSTINE) (AM) IN PATIENTS WITH NON-SMALL-CELL LUNG-CANCER (NSCLC) TREATED WITH CARBOPLATIN (C)
Authors: BETTICHER DC ANDERSON H RANSON M THATCHER N HABBOUBI N MEELY K
Citation: Dc. Betticher et al., A PHASE-II EVALUATION OF BONE-MARROW PROTECTION BY ETHYOL(R) (AMIFOSTINE) (AM) IN PATIENTS WITH NON-SMALL-CELL LUNG-CANCER (NSCLC) TREATED WITH CARBOPLATIN (C), European journal of cancer, 31A, 1995, pp. 1058-1058
SYMPTOMATIC BENEFIT FROM GEMCITABINE AND OTHER CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG-CANCER - CHANGES IN PERFORMANCE STATUS AND TUMOR-RELATED SYMPTOMS
Authors: THATCHER N ANDERSON H BETTICHER DC RANSON M
Citation: N. Thatcher et al., SYMPTOMATIC BENEFIT FROM GEMCITABINE AND OTHER CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG-CANCER - CHANGES IN PERFORMANCE STATUS AND TUMOR-RELATED SYMPTOMS, Anti-cancer drugs, 6, 1995, pp. 39-48
ALTERNATE SPLICING PRODUCES A NOVEL CYCLIN D1 TRANSCRIPT
Authors: BETTICHER DC THATCHER N ALTERMATT HJ HOBAN P RYDER WDJ HEIGHWAY J
Citation: Dc. Betticher et al., ALTERNATE SPLICING PRODUCES A NOVEL CYCLIN D1 TRANSCRIPT, Oncogene, 11(5), 1995, pp. 1005-1011
DIAGNOSIS AND THERAPY OF MULTIPLE-MYELOMA - NEW ASPECTS
Authors: BETTICHER DC CERNY T FEY MF
Citation: Dc. Betticher et al., DIAGNOSIS AND THERAPY OF MULTIPLE-MYELOMA - NEW ASPECTS, Schweizerische medizinische Wochenschrift, 125(11), 1995, pp. 541-551
MELANOMA - CHEMOTHERAPY
Authors: LEE SM BETTICHER DC THATCHER N
Citation: Sm. Lee et al., MELANOMA - CHEMOTHERAPY, British Medical Bulletin, 51(3), 1995, pp. 609-630
TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE IN A PATIENT TREATEDWITH CLADRIBINE (2-CHLORODEOXYADENOSINE) - DEMONSTRATION OF EXOGENOUSDNA IN VARIOUS TISSUE-EXTRACTS BY PCR ANALYSIS
Authors: ZULIAN GB ROUX E TIERCY JM EXTERMANN M DIEBOLDBERGER S REYMOND JM HELG C ZUBLER R BETTICHER DC ALBERTO P JEANNET M CHAPUIS B
Citation: Gb. Zulian et al., TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE IN A PATIENT TREATEDWITH CLADRIBINE (2-CHLORODEOXYADENOSINE) - DEMONSTRATION OF EXOGENOUSDNA IN VARIOUS TISSUE-EXTRACTS BY PCR ANALYSIS, British Journal of Haematology, 89(1), 1995, pp. 83-89
CARBOPLATIN COMBINED WITH AMIFOSTINE, A BONE-MARROW PROTECTANT, IN THE TREATMENT OF NON-SMALL-CELL LUNG-CANCER - A RANDOMIZED PHASE-II STUDY
Authors: BETTICHER DC ANDERSON H RANSON M MEELY K OSTER W THATCHER N
Citation: Dc. Betticher et al., CARBOPLATIN COMBINED WITH AMIFOSTINE, A BONE-MARROW PROTECTANT, IN THE TREATMENT OF NON-SMALL-CELL LUNG-CANCER - A RANDOMIZED PHASE-II STUDY, British Journal of Cancer, 72(6), 1995, pp. 1551-1555
HIGH-INCIDENCE OF INFECTIONS AFTER 2-CHLORODEOXYADENOSINE (2-CDA) THERAPY IN PATIENTS WITH MALIGNANT-LYMPHOMAS AND CHRONIC AND ACUTE LEUKEMIAS
Authors: BETTICHER DC FEY MF VONROHR A TOBLER A JENZER H GRATWOHL A LOHRI A PUGIN P HESS U PAGANI O ZULIAN G CERNY T
Citation: Dc. Betticher et al., HIGH-INCIDENCE OF INFECTIONS AFTER 2-CHLORODEOXYADENOSINE (2-CDA) THERAPY IN PATIENTS WITH MALIGNANT-LYMPHOMAS AND CHRONIC AND ACUTE LEUKEMIAS, Annals of oncology, 5(1), 1994, pp. 57-64
PNEUMOCYSTIS-CARINII PNEUMONIA UNDER THER APY WITH 2-CHLORODEOXYADENOSINE (2-CDA)
Authors: HABERTHUR C PLESS M TICHELLI A GRATWOHL A SPECK B BETTICHER DC
Citation: C. Haberthur et al., PNEUMOCYSTIS-CARINII PNEUMONIA UNDER THER APY WITH 2-CHLORODEOXYADENOSINE (2-CDA), Schweizerische medizinische Wochenschrift, 124(1-2), 1994, pp. 73-78
2-CHLORODEOXYADENOSINE AS TREATMENT OF SEVERE ACUTE GRAFT-VERSUS-HOSTDISEASE
Authors: PLESS M GRATWOHL A TICHELLI A SPECK B BETTICHER DC
Citation: M. Pless et al., 2-CHLORODEOXYADENOSINE AS TREATMENT OF SEVERE ACUTE GRAFT-VERSUS-HOSTDISEASE, Blood, 84(3), 1994, pp. 987-989
Risultati: 1-25 | 26-29